Testing a Tumor Vaccine Plus Vorasidenib for IDH1 Mutant Lower Grade Glioma That Came Back
Original title: ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, mostly checking how safe the treatment is.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a tumor vaccine given with a drug called vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary.
Who this trial is for. This trial is for adults whose IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary mutant lower grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary has come back. It tests a vaccine called PEPIDH1M given with vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary, a drug that blocks mutant IDH1 and IDH2.
Where it stands. There are no results yet. The study is looking at how safe this pairing is, and how well it works. Those answers are not in.
What this means, and what it doesn't
What it could mean: This is one of the ways new options get tested. If your tumor is an IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary mutant lower grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary that came back, you could ask your care team about this study.
What it doesn't mean: This does not mean the vaccine and drug work. A trial is a test, not a proven treatment. Joining a study is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, August 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.